Takeda wins FDA approval for heartburn treatment Kapidex

02/1/2009 | Bloomberg · Chicago Tribune (tiered subscription model)

The FDA cleared Takeda Pharmaceutical's Kapidex delayed-release capsules, which treat gastroesophageal reflux disease. Kapidex is a new formulation of Prevacid, which made up 19% of the Japanese firm's revenue in the quarter that ended Sept. 30.

View Full Article in:

Bloomberg · Chicago Tribune (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ